Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
The NF-κB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma.
[hodgkin lymphoma, classical]
The
NF-
κB
inhibitor
DHMEQ
has
shown
preclinical
activity
in
classical
Hodgkin
Lymphoma
(
cHL
)
.
Here
we
evaluated
if
DHMEQ
could
affect
microenvironmental
interactions
and
formation
and
improve
the
activity
of
drugs
used
in
relapsed
/
refractory
cHL
.
We
demonstrated
that
DHMEQ
down-regulated
the
NF-κB
target
genes
IRF
4
and
CD
40
,
the
secretion
of
IL
-
6
,
CCL
5
,
CCL
17
and
generated
ROS
.
Cytotoxicity
,
CD
30
down-modulation
and
CD
30
shedding
by
DHMEQ
were
prevented
by
ROS
scavenger
NAC
.
DHMEQ
overcame
stimuli
from
CD
40
engagement
and
fibroblasts
and
enhanced
doxorubicin
,
cisplatin
and
gemcitabine
activity
.
Our
results
suggest
that
DHMEQ
may
be
a
promising
agent
for
future
therapeutic
strategies
in
cHL
.
Diseases
Validation
Diseases presenting
"future therapeutic strategies in chl"
symptom
hodgkin lymphoma, classical
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom